SPOTLIGHT: Pfizer top R&D spender worldwide

Pfizer shelled out more on R&D last year than any other company in the world, and drugmakers in general have stepped up their research budgets, the European Commission says. Pfizer spent $8.18 billion, elbowing Ford out of the top slot. Johnson & Johnson came in third. Report

Suggested Articles

Five Prime Therapeutics’ clinical development lead is hoping for a more stable time at new employer Spectrum Pharma.

The update comes as Gilead closes in on a FDA approval that will position it to compete with JAK inhibitors sold by AbbVie, Eli Lilly and Pfizer.

Just weeks after the biotech raised a $63 million round, Accent Therapeutics is striking its first Big Pharma partnership with AstraZeneca.